Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

19.47 +0.21 (+1.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 509,855
Open 18.85
Bid (Size) 19.48 (1)
Ask (Size) 20.15 (2)
Prev. Close 19.26
Today's Range 18.74 - 20.35
52wk Range 6.510 - 33.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia

Performance

YTD
+7.75%
+7.75%
1 Month
+119.01%
+119.01%
3 Month
+51.52%
+51.52%
6 Month
+7.75%
+7.75%
1 Year
+7.75%
+7.75%

More News

Read More
Here's How Citi Views Amylyx Pharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
Via Benzinga
82 Biggest Movers From Yesterday
Via Benzinga
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
Via Benzinga
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
83 Biggest Movers From Yesterday
Via Benzinga
69 Biggest Movers From Friday
Via Benzinga
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
Via Benzinga
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
Via Benzinga
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
Via InvestorPlace
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
Via Benzinga
Former Red-Hot IPO Amylyx Soars On New Hopes For Its ALS Drug
Via Investor's Business Daily
Here's Why Amylyx Pharmaceuticals Shares Are Skyrocketing Today
Via Benzinga
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Via Benzinga
Amylyx Pharmaceuticals Announces Presentation of New Analysis of CENTAUR Trial Results at the European Network to Cure ALS 2022 Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2022
Via Benzinga
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.